CA2812727A1 - Anti-ephrin b2 antibody and its use - Google Patents

Anti-ephrin b2 antibody and its use Download PDF

Info

Publication number
CA2812727A1
CA2812727A1 CA2812727A CA2812727A CA2812727A1 CA 2812727 A1 CA2812727 A1 CA 2812727A1 CA 2812727 A CA2812727 A CA 2812727A CA 2812727 A CA2812727 A CA 2812727A CA 2812727 A1 CA2812727 A1 CA 2812727A1
Authority
CA
Canada
Prior art keywords
polypeptide
antibody
cell
ephrin
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2812727A
Other languages
English (en)
French (fr)
Inventor
Jorge Luis Martinez Torrecuadrada
Maria Angeles Abengozar Infantes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro Nacional de Investigaciones Oncologicas CNIO
Original Assignee
Centro Nacional de Investigaciones Oncologicas CNIO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nacional de Investigaciones Oncologicas CNIO filed Critical Centro Nacional de Investigaciones Oncologicas CNIO
Publication of CA2812727A1 publication Critical patent/CA2812727A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2812727A 2010-09-21 2011-09-20 Anti-ephrin b2 antibody and its use Abandoned CA2812727A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
ESP201031402 2010-09-21
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (1)

Publication Number Publication Date
CA2812727A1 true CA2812727A1 (en) 2012-03-29

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2812727A Abandoned CA2812727A1 (en) 2010-09-21 2011-09-20 Anti-ephrin b2 antibody and its use

Country Status (12)

Country Link
US (1) US9062109B2 (https=)
EP (1) EP2620449A4 (https=)
JP (1) JP2013542720A (https=)
KR (1) KR20140014062A (https=)
CN (1) CN103237812A (https=)
AU (1) AU2011306816A1 (https=)
BR (1) BR112013005977A2 (https=)
CA (1) CA2812727A1 (https=)
ES (1) ES2378976B1 (https=)
MX (1) MX2013003168A (https=)
RU (1) RU2013118454A (https=)
WO (1) WO2012038573A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
EP3969478A1 (en) * 2019-05-14 2022-03-23 Sanford Health Anti-human ephrin b1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
WO2025207820A2 (en) * 2024-03-27 2025-10-02 Mediar Therapeutics, Inc. Anti-ephrin b2 antibodies and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
AU2006308648A1 (en) * 2005-10-31 2007-05-10 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
AR059096A1 (es) * 2006-01-20 2008-03-12 Genentech Inc Anticuerpos anti- efrina -b2 y metodos que usan estos
ES2368764T3 (es) * 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Also Published As

Publication number Publication date
US9062109B2 (en) 2015-06-23
ES2378976A1 (es) 2012-04-19
MX2013003168A (es) 2013-08-21
KR20140014062A (ko) 2014-02-05
EP2620449A4 (en) 2014-03-26
CN103237812A (zh) 2013-08-07
EP2620449A1 (en) 2013-07-31
WO2012038573A1 (es) 2012-03-29
JP2013542720A (ja) 2013-11-28
ES2378976B1 (es) 2013-05-06
US20130287795A1 (en) 2013-10-31
RU2013118454A (ru) 2014-10-27
BR112013005977A2 (pt) 2019-09-24
AU2011306816A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
Kariya et al. Osteopontin in cancer: mechanisms and therapeutic targets
Xu et al. A transient wave of Bhlhe41+ resident macrophages enables remodeling of the developing infarcted myocardium
JP6843754B2 (ja) ピオベルジン及びピオケリンに特異的な新規なタンパク質
CN108840923B (zh) 一种靶向pd-l1的多肽及其应用
CA2812727A1 (en) Anti-ephrin b2 antibody and its use
US20180141988A1 (en) Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
JP2006518991A5 (https=)
Kaira et al. CD98 is a promising prognostic biomarker in biliary tract cancer
CN105734159B (zh) 食管鳞癌的分子标记物
JP6974874B2 (ja) ヒトｐｄ−ｌ１タンパク質に高親和性を有するペプチド及びその使用
Li et al. Dl-3-n-Butylphthalide regulates the Ang-1/Ang-2/Tie-2 signaling axis to promote neovascularization in chronic cerebral hypoperfusion
Wu et al. TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation
Wang et al. The regenerating protein 3A: a crucial molecular with dual roles in cancer
Qian et al. HDAC8 Enhances the Function of HIF‐2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC
Samulevich et al. Critical Analysis of Cytoplasmic Progression of Inflammatory Signaling Suggests Potential Pharmacologic Targets for Wound Healing and Fibrotic Disorders
De Luca et al. Roadmap for stroke: challenging the role of the neuronal extracellular matrix
Schranz et al. Increased level of LIGHT/TNFSF14 is associated with survival in aneurysmal subarachnoid hemorrhage
CN108912212B (zh) 一种与cd105特异性结合的多肽及其应用
JP2013542720A5 (https=)
Jiang et al. Sensor array-enabled identification of drugs for repolarization of macrophages to anti-inflammatory phenotypes
JP2009523004A5 (https=)
Dallatomasina et al. Spatiotemporal regulation of tumor angiogenesis by circulating chromogranin A cleavage and neuropilin-1 engagement
Xie et al. Malignancy‐associated ischemic stroke: Implications for diagnostic and therapeutic workup
Xiao et al. Clinical significance and underlying mechanism of long non‐coding RNA SNHG12 in lower extremity deep venous thrombosis
Xu et al. Screening and functional studies of Norrin-related nanobodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160921